SEHK:2588
SEHK:2588Trade Distributors

BOC Aviation (SEHK:2588): Valuation Check After New Airbus A350-1000 Lease Deal with Philippine Airlines

BOC Aviation (SEHK:2588) just struck a fresh deal to buy two Airbus A350-1000s and lease them back to Philippine Airlines, a classic sale and leaseback that quietly extends its long term revenue runway. See our latest analysis for BOC Aviation. The market seems to be rewarding this steady pipeline of long term leases, with the share price at HK$74.0 and a robust year to date share price return of 26.71 percent, while the 5 year total shareholder return of 43.10 percent points to durable, if...
SEHK:1788
SEHK:1788Capital Markets

Is Guotai Junan International (SEHK:1788) Overvalued After Its Strong Share Price Run?

Guotai Junan International Holdings (SEHK:1788) has been on a rollercoaster lately, with the share price sliding 4 % today and down roughly 12 % over the past month despite a strong year to date. See our latest analysis for Guotai Junan International Holdings. That drop to HK$2.57 gives back some of the huge year to date share price return, but with the 1 year total shareholder return still firmly positive, recent momentum looks more like a breather than a reversal in sentiment. If Guotai...
SEHK:163
SEHK:163Real Estate

Emperor International (SEHK:163) Deepening HK$3.7b TTM Loss Reinforces Bearish Profitability Narratives

Emperor International Holdings (SEHK:163) has posted another tough set of H1 2026 numbers, with total revenue of about HK$1.0 billion and a basic EPS loss of roughly HK$0.25, underscoring that the business is still running in the red. Looking back, revenue has hovered in the HK$0.6 billion range in H1 2025 and H2 2024 while EPS stayed negative between HK$0.25 and HK$0.36, and over the last 12 months the company has remained unprofitable as losses have been compounding at an 18.1% annualised...
SEHK:867
SEHK:867Pharmaceuticals

China Medical System Holdings (SEHK:867): Valuation Check After Y-3 Stroke Drug NDA Acceptance and Phase III Success

China Medical System Holdings (SEHK:867) just cleared a meaningful hurdle, with regulators accepting its New Drug Application for Y-3 for Injection after a successful Phase III trial in acute ischemic stroke patients. See our latest analysis for China Medical System Holdings. Despite a softer 30 day share price return and some recent consolidation, China Medical System Holdings still sits at HK$13.40, with strong upward share price return year to date and a robust multi year total shareholder...
SEHK:9926
SEHK:9926Biotechs

The Bull Case For Akeso (SEHK:9926) Could Change Following FDA Clearance Of Global Gastric Cancer Trial

Akeso has recently reported a series of oncology milestones, including FDA approval to start a global Phase III trial of cadonilimab in advanced HER2‑negative gastric cancer and new Phase II/III data on ivonescimab in triple‑negative breast cancer and squamous non‑small cell lung cancer. Together, these updates underscore Akeso’s push to position its bispecific antibodies as potential new standards of care across multiple solid tumors, supported by both efficacy and quality‑of‑life...
SEHK:9995
SEHK:9995Biotechs

Does RemeGen’s Index Debut on Shanghai’s Health Care Benchmark Reframe the Bull Case For RemeGen (SEHK:9995)?

In December 2025, RemeGen Co., Ltd was added to the Shanghai Stock Exchange Health Care Sector Index, marking its inclusion among China’s listed healthcare names tracked by this benchmark. This index inclusion can increase RemeGen’s visibility to institutional investors that track or reference sector indices, potentially influencing how the company is positioned in healthcare-focused portfolios. With this new index inclusion as a backdrop, we’ll examine how RemeGen’s expanding profile within...
SEHK:992
SEHK:992Tech

Lenovo (SEHK:992) Valuation Check After Major AI-Focused Data Infrastructure Launch

Lenovo Group (SEHK:992) just rolled out a sweeping lineup of AI ready storage, virtualization, and data management offerings, a strategic push that could gradually reshape how investors view its infrastructure and services growth story. See our latest analysis for Lenovo Group. Against that backdrop, Lenovo’s HK$9.66 share price reflects a mixed year, with recent share price returns under pressure but a solid 1 year total shareholder return of about 9.8 percent and strong three year...
SEHK:2367
SEHK:2367Personal Products

Did Giant Biogene’s New Buyback Plan Just Shift Giant Biogene Holding's (SEHK:2367) Investment Narrative?

Earlier in December, Giant Biogene Holding announced a share repurchase plan, following recent analyst coverage from Citic Securities, Citi and UBS. The buyback move is being read as a signal of management confidence and a direct attempt to enhance shareholder value. With the share repurchase plan now in place, we’ll explore how this capital allocation decision shapes Giant Biogene’s broader investment narrative. AI is about to change healthcare. These 30 stocks are working on everything...
SEHK:1983
SEHK:1983Banks

Asian Market Insights: Luzhou Bank And 2 More Promising Penny Stocks

As global markets react to interest rate adjustments and economic uncertainties, investors are increasingly looking toward alternative investment opportunities. The term 'penny stocks' might feel like a relic of past market eras, but the potential they represent is as real as ever. Typically referring to smaller or relatively new companies, these stocks can provide a mix of affordability and growth potential when paired with strong financials.
SEHK:291
SEHK:291Beverage

Assessing China Resources Beer (SEHK:291)’s Valuation After Its Corporate Governance and ESG Excellence Awards Win

China Resources Beer (Holdings) (SEHK:291) just picked up top honors in both Corporate Governance and ESG Excellence Awards, a signal that its sustainability and oversight practices are increasingly aligned with long term, risk aware investors. See our latest analysis for China Resources Beer (Holdings). At around HK$27.0, the shares have delivered an 11.34% year to date share price return. However, the 3 year total shareholder return of minus 44.69% shows the longer term momentum has been...